Biotech | April 13, 2022
Switzerland grants conditional marketing authorisation for Novavax Covid-19 vaccine
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Switzerland
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Switzerland
The first wave of shipments includes several countries, such as Germany, France and Austria
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Canada
Nuvaxovid is the first protein-based Covid-19 vaccine to receive approval for provisional registration in Australia
Nuvaxovid is the first protein-based Covid-19 vaccine granted approval in South Korea
Novavax' vaccine has received authorizations of the vaccine in over 170 countries
Emergency Use Authorisation application request to be submitted following one month required by FDA EUA guidance
SK bioscience secures long-term license to supply the Novavax vaccine for the Korean market
SAGE recommends additional third dose of the vaccine administered to immunocompromised persons
First Emergency Use Listing granted by WHO for a protein-based Covid-19 vaccine
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)